Verrica Pharmaceuticals, based in the United States, specializes in developing innovative dermatology treatments for individuals suffering from skin diseases. The company's ESG score stands at 37.3, categorizing it as high-risk. Their flagship product, VP-102, is designed to treat common warts and molluscum contagiosum.